Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 10/20 | 0.87 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.87 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.87 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL5943392 | 0.94 | OXTR (0.77) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL7623173 | 0.94 | OXTR (0.77) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Lypressin SCHEMBL33287 | 0.94 | OXTR (0.87) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Lypressin SCHEMBL1650587 | 0.94 | OXTR (0.87) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL23382246 | 0.93 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL2687079 | 0.93 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL21131126 | 0.93 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL10053268 | 0.93 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL22511 | 0.93 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL15933169 | 0.93 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10993984-B2 | Terlipressin compositions and their methods of use | CHIASMA, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20190240284-A1 | TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE | AMRYT PHARMACEUTICALS INC. | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10993984-B2 | Terlipressin compositions and their methods of use | PNLIP, LIPC, LIPA | OXTR 2352/4885AVPR1A 309/4885AVPR2 114/4885 |
| US-20190240284-A1 | TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE | PNLIP, LIPC, LIPA | OXTR 2352/4885AVPR1A 309/4885AVPR2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.